Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The treatment landscape for multiple sclerosis (MS) in the U.S. is rapidly evolving, with over 20 immunomodulatory disease-modifying therapies (DMTs) available and more in development. The market…
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Multiple Sclerosis – Access & Reimbursement – Access & Reimbursement – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market continues to evolve as each new approved disease-modifying therapy (DMT) further expands treatment choice. The most recent launches have entered…
Multiple Sclerosis – Current Treatment – Current Treatment: Physician Insights – Multiple Sclerosis (EU5)
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, many of them next-generation alternatives within existing classes. Most…
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Progression Independent of Relapse Activity (US/EU)
Marketed DMTs for multiple sclerosis deliver a high level of efficacy in preventing relapses and relapse-associated worsening of disability (RAW). However, MS patients still experience disability…
Multiple Sclerosis – Geographic Focus: China – Multiple Sclerosis: China In-Depth (China)
Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in that country. Traditionally, MS patients…
